SIRS

evenamide-phase-ii-iii-trial-result

Apr 15, 2024

Evenamide (NW-3509): Advancing Solutions for Treatment-Resistant Schizophrenia

ulotaront-for-schizophrenia-treatment

Apr 15, 2024

Ulotaront (SEP-363856): A New Era in Schizophrenia Treatment

cvl-231-for-schizophrenia-treatment

Apr 12, 2024

A New Dawn: Emraclidine (CVL-231) and the Quest for Effective Schizophrenia Therapeutics

bristol-myers-squibb-karxt-emergent-4-trial

Apr 12, 2024

KarXT: Illuminating Pathways in Schizophrenia Treatment

rl-007-promise-for-cognitive-enhancement-in-schizophrenia

Apr 12, 2024

Beyond Symptom Management: RL-007’s Promise for Cognitive Enhancement in Schizophrenia

lyn-005-in-schizophrenia-treatment

Apr 12, 2024

Breaking Boundaries: The Promise of LYN-005 in Schizophrenia Treatment

iclepertin-for-cias-treatment

Apr 12, 2024

Iclepertin: Bridging the Gap in CIAS Treatment – the Answer to an Unmet Need

brilaroxazine-for-schizophrenia

Apr 12, 2024

Hope on the Horizon: Brilaroxazine’s Promise for Schizophrenia Patients

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper